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Glaucoma is the second leading cause of blindness 
globally. In fact, about 8% of cases of blindness are caused 
by glaucoma worldwide [1]. Elevated intraocular pressure 
(IOP) is the best known risk factor for the development and 
progression of glaucoma; methods of lowering IOP represent 
the cynosure of all glaucoma research. However, after it was 
discovered that oxidative stress injury to retinal ganglion 
cells (RGCs) is a leading pathophysiology of glaucoma [2], 
researchers’ attention has turned to how to directly rescue the 
damaged RGCs from fatal oxidative stress.
Maltol (3-hydroxy-2-methyl-4-pyrone) is a naturally 
occurring aroma compound which is found in beans [3] 
and primarily used as a flavor enhancer. It is also a product 
of the Maillard reaction of Korean red ginseng [4], and it 
is reported to have a strong free radical scavenging activity 
[3,4]. Exogenous maltol administration protects liver cells 
from lipopolysaccharide-induced hepatic damage and kidney 
cells from streptozotocin-induced diabetic renal injuries by 
suppressing thiobarbituric acid reactive substance (TBA-
RS), nuclear factor-κB (NF-κB), and inducible nitric oxide 
synthase (iNOS) [5]. In the nervous system, maltol rescues the 
hippocampal neurons from kainic acid–induced neurotoxicity 
by returning the level of glutathione and TBA-RS to that of 
undamaged animals [6]. RGC axons form the optic nerve that 
transit visual information from the retina to the brain; there 
is no definitive study which has shown that maltol effectively 
protects them from the devastating effects of oxidative stress.
With this in mind, the present study investigates whether 
maltol attenuates oxidative stress injury in primary RGCs 
in vitro. Under oxidative stress, the effects of maltol on cell 
viability, apoptosis, and neurite outgrowth were assessed. To 
better understand its intracellular working mechanism, the 
change in activity of NF-κB was also evaluated.
METHODS
Animals: A total of 48 pregnant Crl:CD-1 mice were 
purchased from Orientbio (Seongnam, South Korea). In 
terms of the mice pups, 676 newborn mice were euthanized 
by decapitation. All animals were treated in accordance with 
the Association for Research in Vision and Ophthalmology 
(ARVO) Statement for the Use of Animals in Ophthalmic 
and Vision Research and the guidelines of the Institutional 
Animal Care and Use Committee of Yonsei University 
College of Medicine, Seoul, Republic of Korea. Great effort 
was made to minimize the number of animals euthanized and 
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Purpose: To evaluate the neuroprotective and neurite outgrowth effects of maltol, a natural aroma compound, on retinal 
ganglion cells (RGCs) under oxidative stress in vitro.
Methods: Mouse primary RGCs were isolated using immunopanning–magnetic separation and exposed to H2O2 in the 
presence of maltol. The cell viability and apoptosis were determined by using adenosine 5′-triphosphate (ATP) assay and 
terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP) nick end labeling (TUNEL), 
respectively. Neurite outgrowth was assessed by immunofluorescence for α-tubulin. The activation of nuclear factor-κB 
(NF-κB) was also evaluated using immunofluorescence.
Results: When the RGCs were exposed to 20 μM of H2O2 for 16 h, their viability dropped to 40.3±3.4%. However, the 
maltol treatment restored the cells in a dose-dependent manner. The viability recovered to 73.9±5.1% with 10 μM of 
maltol and even reached 175.1±11.3% with 2 mM of maltol, as measured by ATP assay. This oxidative stress significantly 
increased the number of TUNEL-positive RGCs, but the maltol drastically reduced the proportion of those apoptotic 
cells. The oxidative stress hampered the neurite outgrowth of the RGCs, whereas maltol restored their ability to sprout 
neurites. Regarding NF-κB, the active form of phosphorylated NF-κB (pNF-κB) increased the oxidative stress level but 
the maltol treatment again reduced it to an unstressful level.
Conclusions: Our data revealed that maltol attenuated the oxidative stress–induced injury in the primary mouse RGCs. 
Its neuroprotective and neurite outgrowth effects seemed to be related to NF-κB signaling. Maltol has potential as a new 
neuroprotective therapeutic agent for oxidative stress–related ocular diseases, including glaucoma.
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their suffering. Each following experiment was conducted in 
quadruplicate and it was repeated at least three times from 
different cell harvests.
Cell culture: Primary mouse RGCs were harvested from 
three- or four-day-old newborn mice using the immunopan-
ning–magnetic separation method, as previously described 
[7]. Briefly, the retinal tissue was separated from the enucle-
ated eyeballs and the mixed retinal cells were collected as a 
suspension. The retinal cell suspension was incubated with 
a rabbit anti-mouse macrophage antibody (Fitzgerald Indus-
tries International, Concord, MA) and distributed over a Petri 
dish coated with a goat anti-rabbit immunoglobulin G (IgG) 
antibody (Southern Biotechnology Associates, Birmingham, 
AL). Nonadherent cells were then treated with a biotinylated 
anti-mouse Thy 1.2 antibody (Abcam, Cambridge, MA) and 
interacted with MACSTM anti-biotin MicroBeads (Miltenyi 
Biotec, Bergisch Gladbach, Germany). The magnetically 
labeled RGCs were finally collected using a magnetic sepa-
rating unit (Miltenyi Biotec). The isolated cells were cultured 
in Dulbecco’s modified Eagle’s medium/nutrient mixture 
F-12 (DMEM/F-12; Catalog no. SH30023.01; Hyclone, 
Logan, UT) containing 10% fetal bovine serum, 100 U/ml of 
penicillin, and 100 μg/ml of streptomycin (Life Technologies, 
Grand Island, NY). The cultures were incubated at 37 °C in 
humidified 5% CO2 and 95% air. For all of the experiments 
conducted, the cells were used at 70–80% confluence. At 24 
h after harvesting, the RGCs were exposed to 20 μM of H2O2 
(Sigma-Aldrich, St. Louis, MO) for 16 h. In the maltol treat-
ment group, various concentrations of maltol (Sigma-Aldrich) 
were added to culture media at the time of injury.
Cell viability: The number of viable cells in the culture was 
determined by quantification of the adenosine 5′-triphosphate 
(ATP) present, which signals the presence of metabolically 
active cells (CellTiter-Glo® Luminescent Cell Viability 
Assay; Promega, Madison, WI). For each well of an opaque-
walled 96-well plate, a volume of CellTiter-Glo® Reagent 
(100 μl) was added to the same volume of cell culture medium 
(100 μl) containing the cells. To induce cell lysis, the contents 
were mixed for 2 min in an orbital shaker. The solution was 
allowed to stabilize for 10 min at room temperature and the 
luminescent signal was then recorded.
Nuclear DNA fragmentation: Apoptotic cells were evalu-
ated using the terminal deoxynucleotidyl transferase 
(TdT)-mediated deoxyuridine triphosphate (dUTP) nick end 
labeling (TUNEL), which detects nuclear DNA fragmenta-
tion by labeling the terminal end of nucleic acids (Apo-BrdU 
In situ DNA Fragmentation Assay Kit; BioVision, Mountain 
View, CA). In brief, the cells were fixed with 1% parafor-
maldehyde for 15 min on ice and 70% ethanol for at least 
30 min at -20 °C. They were incubated with TdT reaction 
buffer, TdT enzyme, and bromolated dUTP (Br-dUTP) for 60 
min at 37 °C and subsequently reacted with the anti-BrdU-
fluorescein isothiocyanate (FITC) antibody in the dark for 
30 min at room temperature. In addition, the cells were coun-
terstained with propidium iodide (PI) in the dark for 30 min 
at room temperature. The cells were finally assessed under 
a fluorescence microscope; the Br-dUTP transferred to the 
free3’-hydroxyl (3’-OH) groups of cleaved DNA and TdT was 
detected. Apoptotic cells showed green fluorescence over PI 
counterstained cells of orange-red fluorescence.
Neurite outgrowth: The cells were fixed with 4% paraformal-
dehyde (Yakuri Pure Chemicals Co., LTD., Kyoto, Japan) for 
30 min, treated with 0.1% Triton X-100 (Sigma-Aldrich) in 
0.1% Na-Citrate (Sigma-Aldrich) for 10 min, and then blocked 
with 2% bovine serum albumin (BSA; Sigma-Aldrich) for 1 h. 
They were incubated with an anti-mouse α-tubulin (1:50 dilu-
tion; Abcam) antibody overnight at 4 °C, and then exposed to 
the FITC-conjugated secondary antibody (1:100 dilution; Life 
Technologies) for 60 min at room temperature. A mounting 
medium containing 4’,6-diamidino-2-phenylindole (DAPI; 
Santa Cruz Biotechnology, Dallas, TX) was applied, and four 
random fields were examined under a confocal microscope. 
α-tubulin was finally detected with FITC, which appeared 
as green fluorescence in neurites, and all nuclei were coun-
terstained with DAPI, which appeared as blue fluorescence.
Activity of nuclear factor-κB: The activity of NF-κB was 
evaluated by immunofluorescence as described above (see 
neurite outgrowth section). Specifically, the NF-κB p50 (1:50 
dilution; Santa Cruz Biotechnology) and pNF-κB p50 (1:50 
dilution; Santa Cruz Biotechnology) primary antibodies were 
used. The original form of NF-κB was labeled with Alexa594 
(Life Technologies) with red fluorescence in the cytosolic 
space, and the active form of pNF-κB was labeled with FITC 
with green fluorescence in the nucleus.
Statistical analysis: Cell viability data were expressed with a 
mean ± standard error of the mean (SEM) and compared with 
the Kruskal–Wallis one-way analysis of variance (ANOVA) 
using the PASW Statistics 18 for Windows, version 18.0.0 
(SPSS, Chicago, IL). A p value of less than 0.05 was consid-
ered statistically significant.
RESULTS
Maltol attenuates oxidative stress–induced cytotoxicity 
of retinal ganglion cells: When the primary mouse RGCs 
were exposed to 20 μM of H2O2 for 16 h, the cell viability 
dropped to 40.3±3.4% compared to the undamaged control 
cells, as measured by ATP assay (Figure 1). Maltol treatment 
improved the cell viability in a dose-dependent manner. It 
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recovered to 73.9±5.1% of that of the control with 10 μM of 
maltol, and even reached 175.1±11.3% of that of the control 
with 2 mM of maltol.
Maltol reduces apoptosis in retinal ganglion cells under 
oxidative stress: Oxidative stress from H2O2 (20 μM, 16 h) 
attacked the primary RGCs in a devastating manner. In the 
undamaged control group, the TUNEL-positive cells with 
green fluorescence were seldom observed (Figure 2A). In the 
oxidative stress only group, the greater part of the cells were 
TUNEL-positive apoptotic cells (Figure 2B). In the maltol 
treatment group, when 1 mM of maltol was added to the 
culture medium at the time of injury, the number of apoptotic 
cells was significantly reduced (Figure 2C). The proportion 
of TUNEL-positive apoptotic cells is quantified and shown 
in Figure 2D.
Maltol restores neurite outgrowth ability of retinal ganglion 
cells damaged by oxidative stress: Primary mouse RGCs 
sprouted many neurites in an unstressful environment (Figure 
3A). These neurites contained a high amount of α-tubulin, 
which assembles the microtubules with β-tubulin. Oxidative 
stress was induced by exposing the cells to 20 μM of H2O2 
for 16 h. Under stress, most of the cells were hampered and 
reached fewer neurites (Figure 3B). However, when 1 mM of 
maltol was added to the culture media during the experiment, 
the RGCs were fairly restored and had the ability to stretch 
their neurites out (Figure 3C). Interestingly, in the presence 
of maltol, the number of RGCs that came into contact and 
interacted with the surrounding cells increased vastly even 
under oxidative stress (Figure 3D).
Maltol suppresses the activation of nuclear factor-κB in 
retinal ganglion cells under oxidative stress: For unstressed 
RGCs, the inactive form of NF-κB was dominant and reacted 
to the anti-NF-κB p50-specific antibody tagged by red fluo-
rescence (Figure 4A). When the RGCs were placed under 
oxidative stress due to exposure to 20 μM of H2O2 for 16 h, 
the active form of pNF-κB increased dramatically and was 
labeled with the anti-pNF-κB p50-specific antibody tagged 
by green fluorescence (Figure 4B). In the presence of 1 mM 
of maltol, the oxidative stress did not significantly influence 
the NF-κB activation. The immunoreactive pattern to NF-κB 
p50/pNF-κB p50 looked similar to that of undamaged control 
cells (Figure 4C).
DISCUSSION
Maltol, a natural organic compound, can act as a free radical 
scavenger [3,4], and protects the neuronal/non-neuronal cells 
from various fatal injuries [5,6]. It saves hippocampal neurons 
from oxidative stress generated by kainic acid, hepatocytes 
from lipopolysaccharide-induced inflammatory damage, 
and renal cells from streptozotocin-induced diabetic injury. 
Although its intracellular working mechanism is still not 
well understood, NF-κB signaling has come to the fore as 
a strong candidate for generating maltol’s cytoprotective 
signaling cascade [5,8]. In the present study, maltol was 
applied on RGCs under oxidative stress in vitro and signifi-
cantly reduced the cytotoxicity caused by H2O2. In higher 
concentrations than 1 mM, maltol raised the cell viability 
to much greater levels than that of undamaged control cells. 
Figure 1. Cell viability was deter-
mined by adenosine 5′-triphos-
phate (ATP) assay. Primary mouse 
retinal ganglion cells (RGCs) were 
exposed to H2O2 for up to 16 h. In 
the presence of maltol, the oxidative 
stress-induced cytotoxicity was 
significantly decreased in a dose-
dependent manner. At concentra-
tions of maltol higher than 1 mM, 
the cell viability became even 
greater compared to the untreated 
control. This ATP assay was 
conducted in quadruplicate and 
repeated at least three times from 
different cell harvests; cell viability 
data were expressed as mean ± 
standard error of the mean (SEM).
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It decreased the proportion of apoptotic cells and restored 
the neurite outgrowth ability of stressed RGCs. These neuro-
protective and neurite outgrowth effects of maltol seemed to 
be related to the NF-κB inactivation. When the RGCs were 
exposed to H2O2, NF-κB was phosphorylated and activated. 
However, in the presence of maltol, the oxidative stress could 
not induce NF-κB phosphorylation. Our results are somewhat 
similar to those of the other previous findings concerning 
maltol’s antiapoptotic effect on human neuroblastoma cells 
[8]; when those cells were exposed to H2O2, maltol drastically 
reduced apoptosis/DNA fragmentation and NF-κB activation.
NF-κB is a transcription factor and plays a key role in 
regulating cellular responses to diverse noxious stimuli [9]. 
While in the latent state, NF-κB is sequestered in the cytosol 
as a complex with inhibitor of κB (IκB), its inhibitory protein. 
When a certain extracellular signal turns on the cascade, IκB 
is phosphorylated and NF-κB cut loose from the inhibitory 
complex. Subsequently, the activated NF-κB translocates 
into the nucleus and binds the target DNA sequences, which 
then finally triggers the target gene transcription. In the 
nervous system, NF-κB plays a complicated dual role [10]. 
According to the stimuli, it turns on the death as well as 
the survival of signaling pathways. For RGCs, pressure- or 
hypoxia-induced activation of NF-κB seems to contribute to 
the cytotoxicity [11-14], and its inactivation appears to protect 
the retina from any damage [13-15]. Our data also suggest 
that maltol protects RGCs from oxidative stress injuries via 
the suppression of NF-κB activation. As a matter of fact, a 
definite conclusion cannot be drawn from this investigation 
that maltol directly suppresses the NF-κB activation and it is 
Figure 2. Apoptosis was evaluated by terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP) nick end 
labeling (TUNEL). Oxidative stress was induced by exposing the retinal ganglion cells (RGCs) to 20 μM of H2O2 for 16 h. In the maltol 
treatment group, 1 mM of maltol was added to culture medium at the time of injury. A: Undamaged control; B: Oxidative stress only; C: 
Oxidative stress with maltol treatment. Apoptotic cells showed broken nuclei with green fluorescence over counterstained, unfragmented 
nuclei with orange-red fluorescence. Scale bar is 200 μm. D: The proportion of apoptotic cells was expressed as mean ± standard error of 
the mean (SEM). Asterisks, p<0.05, n=12, *Significant difference between control versus oxidative stress with/without maltol treatment, 
**Significant difference between oxidative stress without versus with maltol treatment.
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the only mechanism by which maltol rescues the oxidative 
stressed RGCs. Maltol, as an antioxidant, possibly decreases 
the oxidative stress itself, and consequently reduces the stress 
response of NF-κB. In this sense, it seems like a chicken-
and- egg question. However, the direct downregulation of 
NF-κB rescues neurons against acute DNA damage [16], and 
our data are in accordance with this. In addition, even though 
its precise working mechanism is still unclear, it seems to be 
apparent that maltol does indeed diminish RGCs’ oxidative 
damage in vitro.
Glaucoma is a neurodegenerative disease of the optic 
nerve. The retinal nerve fiber layer, which consists of RGC 
axons, is progressively atrophied and the RGC soma gradu-
ally vanishes. Oxidative stress is known to be one of the 
major causes of glaucomatous optic nerve degeneration [2], 
and many researchers are eager to determine how it rescues 
the damaged RGCs from fatal oxidative stress. Several mole-
cules, including α2-adrenergic agonist [17,18], N-methyl-D-
aspartate receptor antagonist [19,20], NOS inhibitor [21,22], 
caspase inhibitor [23,24], and others [25-28], have been 
reported to have neuroprotective effects on experimental 
Figure 3. Neurite outgrowth from retinal ganglion cells (RGCs) was investigated by immunoreactivity to α-tubulin. Oxidative stress was 
induced by exposure to 20 μM of H2O2 for 16 h. In the maltol treatment group, 1 mM of maltol was added to the culture medium at the 
time of injury. A: Undamaged control; B: Oxidative stress only; C: Oxidative stress with maltol treatment. Neurites were labeled with 
green fluorescence and nuclei were counterstained with blue fluorescence. Scale bar is 25 μm. D: The proportion of cells having neurites 
and interacting with surrounding cells was expressed as mean ± standard error of the mean (SEM). Asterisks, p<0.05, n=12, *Significant 
difference between control & oxidative stress with maltol treatment vs. oxidative stress only, **Significant difference between control & 
oxidative stress only vs. oxidative stress with maltol treatment.
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glaucoma models. However, the fruits of all these studies are 
not yet satisfactory, and we still have to dig further to attain 
more conclusive results. Our data suggest that maltol may 
be another candidate for a novel neuroprotective therapeutic 
strategy for oxidative neuronal damage in glaucoma. Apart 
from the influence on the viability of damaged RGCs, the 
ability of maltol to stretch the neurites out from the RGCs 
even in a stressful environment is another outstanding merit. 
Regarding cell-to-cell interaction, maltol treatment appar-
ently increased the proportion of RGCs that came into direct 
contact with the other surrounding cells, even in an environ-
ment of oxidative stress. This phenomenon is supposed to be 
due to the maltol treatment, which subsequently increased 
the cell density or total neurite length. The initial glauco-
matous changes usually begin in RGC axons; thus, how to 
promote axonal regrowth from damaged RGCs is one of the 
major concerns in the glaucoma field. To confirm maltol’s 
neuroprotective and neurite outgrowth effects on RGCs under 
oxidative stress, further in vivo studies are needed, and these 
are currently in progress.
As axonal degeneration precedes cell death, glaucoma 
shares common features with major central nervous system 
(CNS) diseases, including amyotrophic lateral sclerosis, 
Alzheimer’s disease, and Parkinson’s disease [29]. Maltol 
is supposed to be a prospect for the novel neuroprotective/
regenerative therapeutic strategy in these common obstinate 
CNS neurodegenerative diseases related to oxidative stress 
injuries in addition to glaucoma.
In summary, our data revealed that maltol effectively 
attenuates the RGC injury caused by oxidative stress. Maltol 
not only significantly reduced cytotoxicity/apoptosis, but also 
restored the neurite outgrowth ability of damaged RGCs. Its 
capability to protect RGCs and to stretch out neurites seemed 
to be related to the NF-κB signaling pathway. Our data imply 
that maltol may offer a new powerful neuroprotective or 
neuroregenerative therapeutic agent for oxidative stress–
related diseases, including glaucoma.
ACKNOWLEDGMENTS
This work was supported by Basic Science Research Program 
through the National Research Foundation of Korea (NRF) 
funded by the Ministry of Education, Science and Technology 
(No. 2010–0008721 and 2011–0013288) and a grant from 
Yuyu Pharma, Inc. (2011) in Republic of Korea.
REFERENCES
1. Mariotti SP. Global data on visual impairment 2010. Geneva: 
World Health Organization; 2012, p. 3–6.
2. Tezel G. Oxidative stress in glaucomatous neurodegeneration: 
mechanisms and consequences.  Prog Retin Eye Res  2006; 
25:490-513. [PMID: 16962364].
3. Lee KG, Shibamoto T. Antioxidant properties of aroma 
compounds isolated from soybeans and mung beans.  J Agric 
Food Chem  2000; 48:4290-3. [PMID: 10995351].
4. Kang KS, Kim HY, Pyo JS, Yokozawa T. Increase in the free 
radical scavenging activity of ginseng by heat-processing. 
Biol Pharm Bull  2006; 29:750-4. [PMID: 16595912].
5. Yokozawa T, Kang KS, Yamabe N, Kim HY. Therapeutic 
potential of heat-processed Panax ginseng with respect to 
Figure 4. The activity of nuclear factor-κB (NF-κB) was assessed by immunofluorescence for NF-κB p50 and phosphorylated NF-κB 
p50 (pNF-κB p50). Oxidative stress was induced by exposure to 20 μM of H2O2 for 16 h. In the maltol treatment group, 1 mM of maltol 
was added to the culture medium at the time of injury. A: Undamaged control; B: Oxidative stress only; C: Oxidative stress with maltol 
treatment. Unphosphorylated inactive NF-κB was labeled with red fluorescence and phosphorylated active pNF-κB was labeled with green 
fluorescence. Scale bar represents 25 μm.
Molecular Vision 2014; 20:1456-1462 <http://www.molvis.org/molvis/v20/1456> © 2014 Molecular Vision 
1462
oxidative tissue damage.  Drug Discov Ther  2007; 1:30-44. 
[PMID: 22504362].
6. Kim YB, Oh SH, Sok DE, Kim MR. Neuroprotective effect of 
maltol against oxidative stress in brain of mice challenged 
with kainic acid.  Nutr Neurosci  2004; 7:33-9. [PMID: 
15085556].
7. Hong S, Iizuka Y, Kim CY, Seong GJ. Isolation of primary 
mouse retinal ganglion cells using immunopanning-magnetic 
separation.  Mol Vis  2012; 18:2922-30. [PMID: 23233794].
8. Yang Y, Wang J, Xu C, Pan H, Zhang Z. Maltol inhibits apop-
tosis of human neuroblastoma cells induced by hydrogen 
peroxide.  J Biochem Mol Biol  2006; 39:145-9. [PMID: 
16584628].
9. Napetschnig J, Wu H. Molecular basis of NF-κB signaling. 
Annu Rev Biophys  2013; 42:443-68. [PMID: 23495970].
10. Mincheva-Tasheva S, Soler RMNF. -κB signaling pathways: 
role in nervous system physiology and pathology.  Neurosci-
entist  2013; 19:175-94. [PMID: 22785105].
11. Zhou X, Li F, Kong L, Tomita H, Li C, Cao W. Involvement of 
inflammation, degradation, and apoptosis in a mouse model 
of glaucoma.  J Biol Chem  2005; 280:31240-8. [PMID: 
15985430].
12. Hong S, Lee JE, Kim CY, Seong GJ. Agmatine protects retinal 
ganglion cells from hypoxia-induced apoptosis in trans-
formed rat retinal ganglion cell line.  BMC Neurosci  2007; 
8:81-[PMID: 17908330].
13. Sun MH, Pang JH, Chen SL, Han WH, Ho TC, Chen KJ, Kao 
LY, Lin KK, Tsao YP. Retinal protection from acute glau-
coma-induced ischemia-reperfusion injury through pharma-
cologic induction of heme oxygenase-1.  Invest Ophthalmol 
Vis Sci  2010; 51:4798-808. [PMID: 20357190].
14. Tulsawani R, Kelly LS, Fatma N, Chhunchha B, Kubo E, 
Kumar A, Singh DP. Neuroprotective effect of peroxiredoxin 
6 against hypoxia-induced retinal ganglion cell damage. 
BMC Neurosci  2010; 11:125-[PMID: 20923568].
15. Zhou X, Li F, Ge J, Sarkisian SR Jr, Tomita H, Zaharia A, 
Chodosh J, Cao W. Retinal ganglion cell protection by 
17-beta-estradiol in a mouse model of inherited glaucoma. 
Dev Neurobiol  2007; 67:603-16. [PMID: 17443811].
16. Aleyasin H, Cregan SP, Iyirhiaro G, O’Hare MJ, Callaghan 
SM, Slack RS, Park DS. Nuclear factor-(kappa)B modulates 
the p53 response in neurons exposed to DNA damage.  J 
Neurosci  2004; 24:2963-73. [PMID: 15044535].
17. Wheeler LA, Gil DW, WoldeMussie E. Role of alpha-2 adren-
ergic receptors in neuroprotection and glaucoma.  Surv 
Ophthalmol  2001; 45:Suppl 3S290-4. [PMID: 11377451].
18. Lambert WS, Ruiz L, Crish SD, Wheeler LA, Calkins DJ. 
Brimonidine prevents axonal and somatic degeneration of 
retinal ganglion cell neurons.  Mol Neurodegener  2011; 
6:4-[PMID: 21232114].
19. Lipton SA. Possible role for memantine in protecting retinal 
ganglion cells from glaucomatous damage.  Surv Ophthalmol 
2003; 48:S38-46. [PMID: 12852433].
20. Ito Y, Nakamura S, Tanaka H, Shimazawa M, Araie M, Hara 
H. Memantine protects against secondary neuronal degen-
eration in lateral geniculate nucleus and superior colliculus 
after retinal damage in mice.  CNS Neurosci Ther  2008; 
14:192-202. [PMID: 18801112].
21. Neufeld AH. Nitric oxide: a potential mediator of retinal 
ganglion cell damage in glaucoma.  Surv Ophthalmol  1999; 
43:S129-35. [PMID: 10416755].
22. Neufeld AH. Pharmacologic neuroprotection with an inhibitor 
of nitric oxide synthase for the treatment of glaucoma.  Brain 
Res Bull  2004; 62:455-9. [PMID: 15036557].
23. Patil K, Sharma SC. Broad spectrum caspase inhibitor rescues 
retinal ganglion cells after ischemia.  Neuroreport  2004; 
15:981-4. [PMID: 15076719].
24. Schuettauf F, Stein T, Choragiewicz TJ, Rejdak R, Bolz S, 
Zurakowski D, Varde MA, Laties AM, Thaler S. Caspase 
inhibitors protect against NMDA-mediated retinal ganglion 
cell death.  Clin Experiment Ophthalmol  2011; 39:545-54. 
[PMID: 21176044].
25. Fu QL, Wu W, Wang H, Li X, Lee VW, So KF. Up-regulated 
endogenous erythropoietin/erythropoietin receptor system 
and exogenous erythropoietin rescue retinal ganglion cells 
after chronic ocular hypertension.  Cell Mol Neurobiol  2008; 
28:317-29. [PMID: 17554621].
26. Belforte NA, Moreno MC, de Zavalía N, Sande PH, Chianelli 
MS, Keller Sarmiento MI, Rosenstein RE. Melatonin: a novel 
neuroprotectant for the treatment of glaucoma.  J Pineal Res 
2010; 48:353-64. [PMID: 20374442].
27. Roh M, Zhang Y, Murakami Y, Thanos A, Lee SC, Vavvas 
DG, Benowitz LI, Miller JW. Etanercept, a widely used 
inhibitor of tumor necrosis factor-α (TNF-α), prevents retinal 
ganglion cell loss in a rat model of glaucoma.  PLoS ONE 
2012; 7:e40065-[PMID: 22802951].
28. Chen FT, Yang CM, Yang CH. The protective effects of the 
proteasome inhibitor bortezomib (velcade) on ischemia-
reperfusion injury in the rat retina.  PLoS ONE  2013; 
8:e64262-[PMID: 23691186].
29. Coleman MP. The challenges of axon survival: introduction to 
the special issue on axonal degeneration.  Exp Neurol  2013; 
246:1-5. [PMID: 23769907].
Articles are provided courtesy of Emory University and the Zhongshan Ophthalmic Center, Sun Yat-sen University, P.R. China. 
The print version of this article was created on 17 October 2014. This reflects all typographical corrections and errata to the 
article through that date. Details of any changes may be found in the online version of the article.
